Market Snapshot

Study Period: | 2018 - 2026 |
Base Year: | 2021 |
CAGR: | 9.02 % |
![]() |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
- One of the fastest-growing chronic diseases in the world is diabetes. Diabetes is a disease that occurs when the glucose levels in the body increase to more than the average level, and the body unable to produce insulin. Hence, glucometers are used to monitor glucose levels. The Type 1 diabetes population around Europe is rising while witnessing a CAGR of 2.13%. As the diabetic population increases, the self-monitoring blood glucose devices market is also bound to increase.
- Other factors, such as technological innovations, the convenience of regular glucose monitoring over traditional monitoring, and early detection of hypo- and hyperglycemic diabetes, are the major drivers for market growth.
Scope of the Report
The report includes a complete study on self-monitoring blood glucose, which provides glucometer devices, blood glucose test strips, and lancets. The study further divided into hospital usage and home usage.
Self-monitoring Blood Glucose Devices | ||||||||||||
| ||||||||||||
|
By Geography | |||||||||||||||||||||||||||||||||||||
|
Key Market Trends
Germany to lead the Market
- The Increasing in self-monitoring blood glucose market in Europe is due to an increase in diabetes population in all age groups.
- In Germany, the Self-monitoring Blood Glucose Market was estimated to be USD 688.99 million in 2018, which indicates that Germany holds the highest market share at a respectable 36.84% in Europe.
- Diabetes-related complications occur mostly due to poor glucose control results. The market in Germany is expected to show a CAGR of 10.22%, which is one of the highest among the other European countries.
- The meters are now portable and accurate to use since there is an increase in technologies of Glucometers has increased the self-blood glucose monitoring market.

To understand key trends, Download Sample Report
Test Strips is holding the highest market share in Europe Self-monitoring Blood Glucose Devices Market.
- The countries in the Europe region have a high prevalence of diabetes. According to the UK government, the number of people with diabetes has been steadily increasing and tackling it is fundamental to the sustainable future of the NHS. Diabetes can be a severe disease for those that have it and treating it, and its complications cost the NHS almost £10 billion a year.
- The Impact Diabetes report also suggests that the cost of treating diabetes complications is expected to almost double from the current total of £7.7 billion to £13.5 billion.
- Blood glucose monitoring has now become essential to manage diabetes and also to know whether medication is working or not.
- The market for self-glucose monitoring systems has increased more because diabetic people have to test their glucose levels throughout the day. Mainly Type 1 diabetic people must and should check their blood glucose at least three times per day to take their insulin dosage. Blood glucose meter displays the results within seconds and records the data.
- The test strips revenue consist of up to 85% share in Self-glucose monitoring market.

To understand geography trends, Download Sample Report
Competitive Landscape
- The Europe self-monitoring blood glucose devices market is highly fragmented, with few major manufacturers having a global market presence, while the remaining manufacturers confine to the other local or region-specific manufacturers.
- Mergers and acquisitions that occurred between the players in the recent past helped the companies to strengthen their market presence. Panasonic acquired Bayer’s diabetes care unit and named it as Ascensia diabetes care, which continued its operations all over the world.
Major Players

Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Drivers
-
4.3 Restraints
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Bargaining Power of Suppliers
-
4.4.2 Bargaining Power of Consumers
-
4.4.3 Threat of New Entrants
-
4.4.4 Threat of Substitute Products and Services
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 Self-monitoring Blood Glucose Devices
-
5.1.1 By Component (Value and Volume, 2012-2024)
-
5.1.1.1 Glucometer Devices
-
5.1.1.2 Test Strips
-
5.1.1.3 Lancets
-
-
5.1.2 By End User
-
5.1.2.1 Hospital (Value and Volume, 2012-2024)
-
5.1.2.1.1 Glucometer Devices
-
5.1.2.1.2 Test Strips
-
5.1.2.1.3 Lancets
-
-
5.1.2.2 Personal (Value and Volume, 2012-2024)
-
5.1.2.2.1 Glucometer Devices
-
5.1.2.2.2 Test Strips
-
5.1.2.2.3 Lancets
-
-
-
-
5.2 By Geography
-
5.2.1 Europe
-
5.2.1.1 Germany (Value and Volume, 2012-2024)
-
5.2.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
-
5.2.1.1.2 By End User (Hospital and Home)
-
5.2.1.1.3 By Company (Roche, Abbott and Johnson & Johnson)
-
-
5.2.1.2 France (Value and Volume, 2012-2024)
-
5.2.1.2.1 By Component (Glucometer Device, Test strips, Lancets)
-
5.2.1.2.2 By End User (Hospital and Home)
-
5.2.1.2.3 By Company (Roche, Abbott and Johnson & Johnson)
-
-
5.2.1.3 UK (Value and Volume, 2012-2024)
-
5.2.1.3.1 BY Component (Glucometer Device, Test strips, Lancets)
-
5.2.1.3.2 By End User (Hospital and Home)
-
5.2.1.3.3 By Company (Roche, Abbott and Johnson & Johnson)
-
-
5.2.1.4 Russia (Value and Volume, 2012-2024)
-
5.2.1.4.1 By Component (Glucometer Device, Test strips, Lancets)
-
5.2.1.4.2 By End User (Hospital and Home)
-
5.2.1.4.3 By Company (Roche, Abbott and Johnson & Johnson)
-
-
5.2.1.5 Italy (Value and Volume, 2012-2024)
-
5.2.1.5.1 BY Component (Glucometer Device, Test strips, Lancets)
-
5.2.1.5.2 By End User (Hospital and Home)
-
5.2.1.5.3 By Company (Roche, Abbott and Johnson & Johnson)
-
-
5.2.1.6 Spain (Value and Volume, 2012-2024)
-
5.2.1.6.1 By Component (Glucometer Device, Test strips, Lancets)
-
5.2.1.6.2 By End User (Hospital and Home)
-
5.2.1.6.3 By Company (Roche, Abbott and Johnson & Johnson)
-
-
5.2.1.7 Rest of Europe (Value and Volume, 2012-2024)
-
5.2.1.7.1 By Component (Glucometer Device, Test strips, Lancets)
-
5.2.1.7.2 By End User (Hospital and Home)
-
5.2.1.7.3 By Company (Roche, Abbott and Johnson & Johnson)
-
-
-
-
-
6. MARKET INDICATORS
-
6.1 Type-1 Diabetes population (2012-2024)
-
6.2 Type-2 Diabetes population (2012-2024)
-
-
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
-
7.1.1 Abbott Diabetes Care
-
7.1.2 Roche
-
7.1.3 Johnson & Johnson
-
7.1.4 Arkray
-
7.1.5 Ascensia Diabetes Care
-
7.1.6 Agamatrix Inc.
-
7.1.7 Bionime Corporation
-
7.1.8 Acon
-
7.1.9 Medisana
-
7.1.10 Trivida
-
7.1.11 I-SENS
-
7.1.12 Morepen Laboratories
-
7.1.13 Rossmax
-
-
7.2 COMPANY SHARE ANALYSIS
-
7.2.1 Roche
-
7.2.2 Johnson & Johnson
-
7.2.3 Abbott Diabetes Care
-
7.2.4 Others
-
-
-
8. MARKET OPPORTUNITES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Europe Self-monitoring Blood Glucose Devices Market market is studied from 2018 - 2026.
What is the growth rate of Europe Self-monitoring Blood Glucose Devices Market?
The Europe Self-monitoring Blood Glucose Devices Market is growing at a CAGR of 9.02% over the next 5 years.
Who are the key players in Europe Self-monitoring Blood Glucose Devices Market?
Roche, Abbott Diabetes Care, Lifescan, Ascensia, Sanofi(Agamatrix) are the major companies operating in Europe Self-monitoring Blood Glucose Devices Market.